We discuss inference for longitudinal clinical trials subject to possibly informative dropout. A selection of available methods is reviewed for the simple case of trials with two timepoints. Using data from two such clinical trials, each with two treatments, we demonstrate that different analysis methods can at times lead to quite different conclusions from the same data. We investigate properties of complete-case estimators for the type of trials considered, with emphasis on interpretation and meaning of parameters. We contrast longitudinal and crossover designs and argue that for crossover studies there are often good reasons to prefer a complete case analysis. More generally, we suggest that there is merit in an approach in which no untestable assumptions are made. Such an approach would combine a dropout analysis, an analysis of complete-case data only, and a careful statement of justified conclusions.
Introduction
Over the last 20 or so years an impressive array of methods has been developed for missing data problems in general and dealing with dropout in longitudinal trials in particular. [1] [2] [3] [4] [5] [6] [7] [8] Many of these contributions have been deeply thought-provoking and technically highly accomplished. Nevertheless, whatever the technical virtuosity of these methods they cannot make missing data appear. As has been widely recognised, 9 almost all of the methods rely for their validity either on questionable assumptions about the missingness process, or by making untestable assumptions with regard to unobserved outcomes. Consequently it is now generally accepted, and formally recommended, 8 that an analysis of data subject to missingness should include a careful assessment of sensitivity of conclusions to the underlying assumptions.
In this article we take a different view. We use two simple two-timepoint randomised trials to illustrate some of the techniques now available for dealing with dropout from longitudinal data, and as a basis for discussion of a number of foundational issues. We will argue that dropout from a longitudinal clinical trial should not be treated as a special case of a generic missing data problem, but as a different case, since the special role of time should be taken into account. We will suggest that a structured analysis that does not rely on untestable assumptions can in certain circumstances be not just a practicable but an appropriate strategy. In particular, for the situations in which a crossover trial is applicable we will propose that a complete case analysis provides a proper basis for inference.
When dealing with generic missing data it is customary to begin by introducing notation (Y obs , Y miss ) for observed and missing components of a response vector Y. Alongside this we have a vector R of response indicators, with elements taking the value one if the corresponding element of Y is observed, zero otherwise. The familiar Rubin classification of missingness mechanisms is Missing
and otherwise Missing Not at Random (MNAR). It is recognised that an appropriate analysis based only on Y obs can provide unbiased parameter estimates if the missingness is assumed to be MCAR or MAR. However, the validity of these assumptions cannot be detected without imposing additional untestable structure, such as embedding a MAR model within a broader MNAR one, which cannot be unique. 9 Not all writers have fully accepted the Rubin missing data taxonomy or its generic application to longitudinal data, for example. [10] [11] [12] Diggle et al. 11 assert that the notation (Y obs , Y miss ) is too simplistic when missingness is caused by dropout in a longitudinal study. The argument is that the notation Y miss suggests that the underlying unobserved response is the same whether or not it is observed. This is appropriate when the process that generates the missingness pattern is exogenous to the process that generates the responses. Data may still be MNAR, for example if an experimenter simply chooses not to record very low values, but the extant value attached to the experimental unit does not in itself change depending on whether or not it is observed. However, dropout in a longitudinal trial often corresponds to an event in a subject's life, such as withdrawing from treatment. Meinert 13 makes the important point that such treatment dropouts must be distinguished from analysis dropouts, those who simply cease to be observed. Clearly what happens after dropout could be very different from what might have happened in the absence of dropout. In other words if Y miss was not missing it could be something completely different. Considering dropout caused by death makes this point rather dramatically. 14 Building from Diggle et al. 11 we suggest that the use of counterfactual notation should be taken up more widely. We can think of potential outcomes Y t (0) and Y t (1) that correspond, respectively, to the response when external intervention is not, or is, employed to prevent dropout. As Didelez 15 argues in her discussion of Diggle et al., such counterfactuals can be sensibly defined and modelled provided the hypothetical intervention is made explicit; it makes little sense to talk about a response Y t 'in the absence of dropout' without specifying how this absence is to be achieved. Note that we are indexing by dropout (prevention) and not conditioning on it, a distinction also made in Rubin's causal model. 16 Such notation helps make explicit the implicit assumption in most previous work that the properties of Y t (1) are usually the targets for inference. Aalen and Gunnes 12 discuss the complexities of attempting to separate a longitudinal response from the process that may cause it to be missing, and describe why different inferential objectives may be appropriate in different circumstances. Buyse 17 takes a holistic view, and invites subject-matter experts to form a hierarchy of contrasts that may include both longitudinal responses or survival outcomes, in order to compare individuals undergoing different treatment regimes.
In this work we consider targets for inference for simple two-period clinical trials. Our notation, assumptions and a short review of a selection of available methods are given in Section 2.
In Section 3 we present analyses of two such trials, each designed to compare two treatments and in each of which a number of subjects dropped out before the second measurement was collected. We show that a wide range of treatment effect estimates can be obtained, depending on the method and assumptions adopted. Section 4 includes some technical work on the properties of completecase estimators for two-treatment two-period designs. In Section 5 we argue that a transparent approach to an analysis of this type of data requires a combination of a dropout analysis, a complete case analysis, and a careful statement of conclusions that takes full account of the context of the analysis.
Notation, assumptions and methods 2.1 Methods
Suppose there are n subjects in a study and two observation or treatment periods. Subjects provide a measurement at time 1, denoted Y i1 for subject i, but some subjects drop out before measurement time 2. Let R i ¼ 1 indicate continuation to time 2 and R i ¼ 0 otherwise. The possibly counterfactual second response, assuming hypothetically that dropout may be prevented, is Y i2 (1). For simplicity we will denote this by Y i2 but throughout we bear in mind that our models and assumptions are predicated upon a possible counterfactual.
A raft of techniques is available for estimation, some of which are summarised here. We do not attempt a full review and our list is certainly incomplete, with pattern mixture modelling, multiple imputation 18 and Bayesian methods notable omissions. 5 We focus in the main on methods where the estimating equations can be written down in fairly simple form.
Complete case (CC)
Estimation is restricted to subjects who provided both measurements and there is no estimation or use of dropout probabilities. A variety of approaches are possible but a random intercept model with Gaussian errors is common. If the marginal var(Y i ) ¼ AE is known, the maximum likelihood estimator solves the score equation
In practice AE would be unknown and simultaneous estimation of AE and is required.
Last observation carried forward (LOCF)
A procedure that has been common in practice, though much criticised, 3, 8 is to carry forward the last observed value and then pretend the data are complete. Let
Then the LOCF score corresponding to (1) is
with the same comments on variance estimation.
Linear mixed effect (LME)
Maximum likelihood estimation using only observed data yields consistent estimators under MAR, without use of dropout probabilities. 4 Assuming a Gaussian random intercept model, the score equation of current interest is
where x T i1 is the first row of X i and 2 1 ¼ varðY i1 Þ.
Diggle Kenward (DK)
Diggle and Kenward 19 take a fully parametric approach, combining assumptions of multivariate Gaussian response and logistic dropout probabilities. For the remainder of this article we will assume
where we use expit(u) to denote exp(u)/(1 + exp(u)) and ¼ ( 0 , 1 ). Taking 2 ¼ 0 gives MAR dropout and 1 ¼ 2 ¼ 0 gives MCAR. Diggle and Kenward 19 propose likelihood inference based on a selection factorisation. 20 In our terms the likelihood is
The contribution P(
) by integrating out Y 2i with respect to its Gaussian conditional distribution given Y i1 . Diggle and Kenward suggest a probit approximation to logistic in order to obtain a closed form for P(
The same approximation will prove very useful to us in Section 4.
Linear increments (LI)
Diggle et al. 11 model the increments between observations at consecutive measurement times, taking a martingale approach which has links with methods for event history analysis. There are no distributional assumptions for either response or dropout, other than linear models for the mean increments in responses and a martingale assumption for within-subject random effects. Their method is chiefly designed for processes in which the parameter in the linear predictor for the mean is assumed to vary with time. It can be extended in several ways, 21 and can be adapted to give estimates of effects that are assumed to be time-constant, in our case as follows. Let
; elements of the latter will be zero where covariates are constant between measurement times. Recall that E½Y i1 ¼ x T i1 and note that E½D i ¼ d T i . Ordinary least squares can be used to estimate , leading to the estimating equation
2.1.6 Inverse probability weighted estimating equations with MAR assumption (IPMAR) In a series of papers, [22] [23] [24] Robins and colleagues proposed inverse probability of observation weighted estimating equations. Again, no distributional assumptions are made about Y i , other than a linear model for the mean, but a parametric model for dropout probability is required. Although the authors discuss a variety of efficient estimating procedures, for our purposes it is sufficient to concentrate on the simplest version of the proposals. In this case 2 in (4) is assumed known and the other dropout parameters ¼ ( 0 , 1 ) are estimated using the estimating equations
The parameter of interest is then obtained by solving the weighted estimating equation
In the sequel we will refer to the combination of (7) and (8) under the MAR assertion that 2 ¼ 0 as IPMAR.
Inverse probability weighted estimating equations with zero interaction procedure, IPZI, IPZI+ and IPZIÀ
There are no methods for estimating 2 in (4) without further strong assumptions. Instead, in order to apply (8) in the MNAR case it is usually recommended [24] [25] [26] that an expert from the application area be asked to specify either 2 itself or a realistic range within which it could feasibly lie. In the latter case the advice is usually to vary 2 across the range and inspect the consequences for estimation of , or perhaps to elicit a prior distribution for 2 or a related quantity and derive an appropriate posterior summary. 27, 28 Application experts with the required abilities are likely to be in high demand, so there is merit in exploring whether, in specific applications, more oblique approaches to sensitivity analysis might pay dividends. Ho and colleagues 29 propose one such alternative, in which one untestable assumption is traded for another. For crossover trials they propose that the value of 2 that minimises the estimated treatment by period interaction is sought. The resulting value, say 20 , is then taken as the presumed value of 2 in an analysis based on (7) and (8) which now excludes by construction the possibility of interaction. Bootstrap methods can be used to estimate the uncertainty attached to 20 .
Ho et al.'s suggestion was aimed at crossover trials, where washout periods are specifically included in carefully designed trials precisely to limit the possibility of interaction. It can be applied more generally, however, if we are prepared to make a zero interaction assumption. In many cases it may be more straightforward to discuss such an assertion with subject-specialist collaborators than to discuss possible values of the more abstract 2 .
We will refer to the use of the inverse probability weighted estimating equations (7) and (8) with 2 ¼ 20 specified to give zero estimated interaction as IPZI. To get some idea of sensitivity we also propose that the parameters be estimated at 2 ¼ 20 + 2SE( 20 ) (IPZI+) and at 2 ¼ 20 À 2SE( 20 ) (IPZIÀ).
Testable assumptions and the role of time
Most of the foregoing approaches are based on variants of selection models, in that they are rooted in the distributions f(Y 1 , Y 2 ) and f(R W Y 1 , Y 2 ). Pattern mixture alternatives 4, 30 would be based on the marginal f(R) and a mixture over
In Section 1 we stated that dropout in longitudinal trials should be treated as a different type of missing data problem, rather than as a special case of a more generic approach. Both pattern mixture and selection model classes are applicable to generic missing data problems and neither is explicitly based on the fundamental feature of longitudinal studies: events happen and conditions change as time proceeds inexorably. In this section we consider how best to recognise temporal development, and, pre-empting later detailed discussion, suggest that there can be situations where avoiding untestable assumptions can lead to clearer and potentially more pertinent understanding of a longitudinal study.
Our suggestion is to employ only those features of pattern mixture and selection models that do not require untestable assumptions, and in neither case to combine them. An unavoidable feature of this approach is added complexity. Crucially, this complexity lies not in mathematical subtleties, but in the required depth when reporting study findings.
Pattern mixture models offer several advantages in a longitudinal dropout context. Most importantly, definitions of random variables are entirely unambiguous, for longitudinal responses are only modelled conditional on their existence, obviating the need for subtle counterfactual descriptions. 11 The mixing is done over a clearly identified distribution -the marginal distribution of the dropout indicator R -and familiar tools for longitudinal data analysis may be used to model the conditional distributions f(
However, making the latter distribution the subject of a model has the disadvantage that it has no mechanistic interpretation. Because the observation of Y 1 necessarily precedes the realisation of R, the model can provide no insight into the causal mechanisms that may underlie the data. The reverse is true, too: any substantive insights into the causal mechanisms linking previous responses to subsequent dropout cannot easily be incorporated into pattern mixture models. Aalen and colleagues 31, 32 have written about the need for greater recognition of the special role of time, and the ability to reason causally, in the analysis of longitudinal data.
Selection models 4 do admit causal (or mechanistic) thinking, by modelling the probability of dropout conditional on previous observed responses, f(R ¼ 0 W Y 1 ). The corresponding disadvantage comes when attempting to combine these dropout probabilities into a full, joint likelihood: we then require marginal joint distributions of potentially unobserved random variables (e.g. f(Y 1 , Y 2 )) with the accompanying ambiguities of definition.
We can follow a middle path by avoiding the mixing aspect and not attempting to specify a full joint likelihood. Consequently, we are able to restrict ourselves to models requiring no untestable assumptions. Moreover, the features of the analysis strategy we suggest have a natural temporal progression, allowing causal thinking at each stage. We propose (1) Baseline analysis: model f(Y 1 ). The first observation is observed for all subjects, and yields the first opportunity to consider covariate effects on the longitudinal response. 
The first two points are uncontroversial. In subsequent sections we shall consider in greater detail the third component, including our claim that scientific understanding may in some instances be no less complete when considering only complete cases at the second timepoint. Our temporal sequence is reminiscent of the careful likelihood construction of Tsiatis and Davidian. 33 By deliberately avoiding combining these components, we do not specify a joint likelihood for R, Y 1 and Y 2 . More than this, we cannot uniquely specify such a likelihood without further structures or identifying assumptions. Our feeling is that this is a strength, not a weakness.
Illustrations
We consider data from two clinical trials, each with two treatments and two measurement times.
A longitudinal trial with dropout
We first consider results on 422 subjects in an AA/BB longitudinal trial. The data are real but not public. The trial was randomised and observations were taken pre-randomisation and at two times post-randomisation: in this article we consider only the post-randomisation observations. For confidentiality reasons we have scaled all observed responses by the mean and standard deviation of the responses at time 1 and we will refer simply to treatment and response without describing what they are.
There are no covariates other than treatment type and time. Without treatment by time interaction the parameter vector is ¼ (, p, ) , where is a general mean, p measures the effect of time and measures the treatment effect. The design matrices X i are all either
depending on whether the subject is given treatment A or B respectively. Interest is ostensibly in .
All 422 subjects provided a response at time 1. Of 212 subjects receiving Treatment A, only 126 provided a response at time 2 and the other 86 dropped out. We have no information on reason for dropout. Of 210 subjects receiving Treatment B, 193 continued to time 2 and the other 17 did not.
Treatment effect estimates using the techniques described in Section 2 are shown in Figure 1 together with nominal 95% confidence limits. The estimates correspond to the methods summarised in Section 2. The strongest treatment effect is evident under LOCF, with complete case (CC) providing the least evidence of a difference between treatments. The four inverse probability weighted methods are rather similar, and in most cases these techniques have higher standard errors.
It is interesting to explore these data a little further. Figure 2 shows a variety of mean responses, alongside each of which is given the number of observations used in the calculation. Standard deviations are not given but all are relatively small. Panel (a) of the figure is essentially that used in the original trial report to summarise the data. It uses LOCF to interpolate missing values at time 2, so that means are formed from the same number of observations at each time point. Evidently there is a large treatment effect. Panel (b) shows the means of only the observed data. Now the treatment effect seems to disappear at time 2. Its presence at time 1 is not surprising because subjects had already been on treatment for some time before this response was collected, it was not a baseline score. Panel (c) is the most informative presentation of the data: it separates the subjects at time 1 into those who subsequently drop out and those who continue to time 2. Subjects who drop out tend to have lower scores at time 1. Amongst the complete cases there is no evidence of a treatment effect.
A crossover trial with dropout
Our second example is on data from an AB/BA crossover trial. The trial is reported in Frank et al. 34 and is used to illustrate the Zero Interaction proposal. 29 The treatments are analgesics: dihydrocodeine (A) and nabilone (B) and the response was a visual analogue score for pain.
At time 1 we have data on 37 subjects in the AB group and 45 in the BA group. Five of the AB subjects and 10 of the BA subjects dropped out before the time 2 response was recorded. The trial, in common with many crossover trials, required the subjects to receive treatment over a fairly long time interval, in this case six weeks. Thus the subjects who dropped out before the time 2 response are extremely likely to have had some experience of their second treatment. There are again no covariates other than treatment type and time. Without treatment by time interaction the parameter vector is ¼ (, p, ) and the design matrices X i are all either
depending on whether the subject is given treatment in order AB or BA respectively. Figure 3 shows the range of treatment effects obtained using the methods we have described. It seems there are relatively little differences between estimates, which is not surprising as the proportion of dropouts is low (15/92 or 16%). However, some of the differences are marked and there is wide variation in estimated standard errors. The estimated treatment effect under complete case for instance is ¼ À2:85 (SE 1.19), which is little more than half that obtained under the ZI procedure ( ¼ À4:862, SE 2.68).
Complete-case analyses 4.1 Relationship of CC estimators to MNAR estimators
If the distribution of Y i2 (0) is not the same as that of Y i2 (1), then an analysis that attempts to compensate for the missing data, for example by assuming data are MNAR, is of no merit. If the data were not missing, then in almost all circumstances they would be expected to have a different distribution. In such instances the temporal strategy of Section 2.2, including a CC analysis, should be preferred. Nevertheless, the effect on the required inferences of this choice is of practical importance, so an exploration of the properties of a CC analysis when the data are MNAR is of interest.
One such property is the expectation of the estimators of the treatment effect, LONG for the longitudinal study, and CO for the crossover design from a CC analysis. For the simple two-period designs the estimators are
where " S AA denotes the mean of the S i ¼ Y i1 + Y i2 for complete cases in sequence AA, with the other terms defined similarly and with D i ¼ Y i1 À Y i2 . These estimators are unbiassed in the sample space of complete cases and we denote their expectations by CC LONG and CC CO , respectively. These parameters will, in general, differ from the treatment effect introduced in Section 3.1 that would apply if, e.g. a MNAR analysis were used when the distribution of Y i2 (R i ¼ 0) did coincide with that of Y i2 (R i ¼ 1). Analytic approximations for the relationship between these parameters can be derived if we are prepared to assume that the distribution of (Y 1 ,
The key quantities required are
for each of the sequences in the longitudinal trial, and 9 (Y i1 À Y i2 W R i ¼ 1) for the sequences of the crossover design. Omitting the subscript i, these can be evaluated as
If the unconditional mean of Y ij in sequence rs is rsj then the above can be written as
where Â rs ¼ 0 + 1 rs1 + 2 rs2 and (Z 1 , Z 2 ) T is a bivariate Normal variable with mean zero, dispersion matrix and density 2 (z 1 , z 2 W ). We will assume that the variances in are both equal to 2 and that the covariance is 2 . The integrals can be approximated if we note that expit(u) & È(cu) where È(Á) is the standard Normal distribution function and c ¼ ð16 ffiffi ffi 3 p Þ=ð15Þ: 35 A convenient method of evaluation is to note that È(c[Â rs + 1 z 1 + 2 z 2 ]) 2 (z 1 , z 2 W ) is proportional to the density of an extended skew-Normal (ESN) distribution (see Appendix and Arnold and Beaver 36 ), and the normalising constant is the denominator of (9), after the application of the approximation to expit(Á).
Applying the formula for the expectation of the ESN we obtain
q and e T AE ¼ ð1, AE 1Þ. Also z(u) ¼ (u)/È(u), with (u) denoting the density of a standard Normal variable.
From these expressions we can approximate CC LONG and CC CO , using the parametrisation introduced in Section 3.1, when the data are MNAR with continuation probability expit( 0 + 1 Y 1 + 2 Y 2 ). For the longitudinal design we obtain
and for the crossover design
For the longitudinal design Â AA ¼ Â + ( 1 + 2 ) and Â BB ¼ Â À ( 1 + 2 ), with Â ¼ 0 + ( 1 + 2 ) + p( 1 À 2 ), whereas for the crossover design we have Â AB ¼ Â + ( 1 À 2 ) and
. If the deviations of the Â rs from Â are small then (10) and (11) can be written as
Since z 0 (u) ¼ Àz(u)(u + z(u)) < 0 for all u, it follows that both CC LONG and CC CO are shrunk versions of , i.e. they are closer to zero than . Consideration of (10) and (11) shows that the biases operate in the same direction even when the deviations are not small.
If the treatment effect vanishes then it follows that Â rs ¼ Â and hence CC LONG and CC CO also vanish. These expressions also reveal that CC analysis and the MNAR analysis coincide if the data are MCAR ( 1 ¼ 2 ¼ 0). They do not agree when the data are MAR but not MCAR ( 2 ¼ 0, 1 6 ¼ 0). However, if data are MNAR they do agree in some special cases. For the longitudinal design this occurs when 1 ¼ À 2 and, for the crossover design, when 1 ¼ 2 . Some insight into this circumstance can be found by rewriting (4) as
If 1 ¼ 2 then the dropout probability depends on the data only through S i , that is the chance of dropping out depends on the mean level of the response, whereas if 1 ¼ À 2 then the dropout probability depends only on the increments in response, D i . In the longitudinal design the estimate of the treatment effect depends solely on the mean level of the response. If 1 ¼ À 2 , then the probability of dropping out of the study will depend only on the increments in response, and our error model ensures that S i and D i are independent, so the coincidence of and CC LONG is unsurprising. By contrast in the crossover design, the MNAR and the CC estimands coincide if the dropout probability depends only the S i . This result is reminiscent of Little's observation that in a pattern-mixture model intended to estimate the mean difference between period 1 and period 2, a CC analysis is to be preferred if the dropout probability depends on S i . 37 
Meaning of parameters
When interpreting the relationships derived above it is important to remain clear about the meanings of the parameters , CC LONG and CC CO . In Section 3.1 it was stated that is the parameter of interest. However, while this would be so for most standard analyses, a case can be made that this is not always the correct target for our inference.
Consider a crossover design to compare two active treatments, in which some subjects are unable to tolerate one or other of the treatments. In this case the response that would have been observed had the subject tolerated the treatment is not meaningful. In these circumstances a MNAR analysis is inappropriate. On the other hand a CC analysis might be justified on the grounds that it compares subjects who can tolerate both treatments. The validity of this analysis stems from the fact that it is precisely for these subjects that the trial comparison is relevant. The decision to specialise the analysis to this subgroup means that the appropriate target for inference is CC CO .
Even in circumstances where it makes sense to identify Y t (1) and Y t (0), a MNAR approach may not be the right analysis. Consider for instance an analgesic trial in which all subjects can tolerate both treatments, but some drop out because of a side-effect which makes the treatment impractical. For example, subjects on a particular treatment may not be allowed to drive and hence some may refuse the treatment. While one can now sensibly believe that both potential outcomes have the same distribution, the side-effect means that both treatments are a practical proposition only for a subset of subjects and the most pertinent analysis is provided by the complete cases. In this case it is doubtful if the dropout model (4) with the outcomes as the only covariates would adequately describe the missingness process. It could be argued that it is unfair to dismiss a MNAR analysis if the dropout model is mis-specified but, nevertheless, in such an example a CC analysis has the advantages that it is practical, germane and has a readily described rationale.
Discussion
In Section 4.2 we argued that that there are circumstances where the complete case parameters CC CO or CC LONG are the natural parameters of interest. In other situations the underlying parameter may indeed be the original target for inference but if the data are blighted by significant dropout it may be unreasonable to attempt to estimate this inestimable parameter given the data to hand. In these circumstances a CC analysis may be the only practical alternative, but if really is the appropriate target for inference, is this adequate? If the overall level of missingness is low then a CC analysis is unlikely to differ substantially from more sophisticated analyses. Indeed, analyses that link the estimation of treatment parameters to parameters describing dropout may be compromised if there is limited information on the dropout process. On the other hand, as the proportion of the patients in the trial who are retained in a CC falls, the CC analysis will provide useful information about a smaller and rather different population from that originally envisaged. However, as we have argued, this subset of patients may be of particular relevance. In these circumstances a supplementary analysis that seeks to determine the factors affecting dropout becomes necessary.
Consider the longitudinal data of Section 3.1. If the sole focus is on then Figure 1 shows that we can choose any or none of a range of estimates. But Figure 2 summarises the true picture and we suggest that an appropriate analysis should proceed as described in Section 2.2. First we analyse Y 1 only and find and report a strong treatment effect to this time of 0.55 units with standard error 0.09. Such an analysis is sensible for these data because the time 1 measurement is not baseline as the subjects had already received treatment before the measurement was obtained. Second we model dropout as a logistic model in either Y 1 only or, with the remarks of Section 4.2 in mind, in Y 1 and treatment (or other covariates). Omitting details, it turns out that for these data there are strong effects on dropout of both Y 1 and treatment group. These should be discussed with the experimenter. Finally, we perform a complete case analysis and state that for subjects who continue to the second time point there is no evidence of difference between treatment groups in mean response levels at either time point. The conclusions are more complex than initially desired but then so are the data.
A CC analysis of a randomised trials will suffer from the complication that the groups of complete cases will not exhibit the balance conferred by the initial randomisation. The effect of this on inferences will need to be considered carefully if a CC analysis is being considered as the primary analysis. In our examples this issue may be less of a concern in the CO study, as here each patient is essentially used as their own control. An imbalance between the sequences could masquerade as a treatment by period interaction but, if the investigator is confident that the design has excluded carryover effects, such interactions are likely to represent differences in overall level of response, and the D i will be unaffected. The problem of loss of balance in randomised groups is likely to pose a greater challenge for the parallel-group design.
An abiding concern of investigators is the loss of efficiency that results from missing data. This problem may seem to be exacerbated if a CC analysis is used, as data from partially observed cases is ignored. However, the relative efficiencies of alternative analyses should only be a concern if both approaches estimate the same quantity. If data are MNAR then methods such as those exemplified in the Section 2 will not, in general, estimate the same quantity. Consequently, the relative performance of these methods cannot be assessed through simple comparisons of standard errors.
While there may be arguments in favour of CC analyses, there could be circumstances where what constitutes a CC analysis is unclear. In our examples matters are straightforward but consider a crossover trial comparing three treatments over three periods. Suppose that it is required to estimate the contrast between two of the treatments. Does a CC analysis retain only patients providing three observations, or should we use all patients who provide information on the two treatments being compared? The issue becomes even murkier if we consider long sequences of irregularly timed measurements, especially common in observational data rather than designed trials.
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